Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Filters applied. Clear all
Case Reports
. 2012;78(1):54-8.
doi: 10.1159/000339469. Epub 2012 Jul 20.

Treatment With Glucagon-Like Peptide-1 Agonist exendin-4 in a Patient With Hypothalamic Obesity Secondary to Intracranial Tumor

Affiliations
Case Reports

Treatment With Glucagon-Like Peptide-1 Agonist exendin-4 in a Patient With Hypothalamic Obesity Secondary to Intracranial Tumor

Jill H Simmons et al. Horm Res Paediatr. .

Abstract

Background/aims: Patients with hypothalamic tumors frequently experience severe obesity, and its treatment with diet, exercise, and/or pharmacologic treatment has had limited effect. Glucagon-like peptide-1 agonist exenatide (exendin-4), used for treatment of type 2 diabetes, causes persistent weight loss via signaling in the brainstem.

Methods: We report the case of a 17-year-old patient with obesity resulting from a hypothalamic germ cell tumor. He was treated by chemoradiotherapy and exenatide at a dose of 5 µg subcutaneously twice daily.

Results: Exenatide resulted in a 29-kg weight loss (BMI reduction from 37.1 to 29.1) after 2.5 years of treatment; significant weight gain occurred shortly after exenatide was discontinued.

Conclusion: Exenatide resulted in considerable reduction of body weight in a patient with severe hypothalamic obesity. This novel observation requires follow-up clinical studies for establishing the effects of exenatide in patients with disrupted hypothalamic energy regulatory pathways.

Similar articles

See all similar articles

Cited by 3 articles

Publication types

MeSH terms

Feedback